[Treatment of Cystic Fibrosis with CFTR Modulators].

doi:10.1055/s-0042-100607

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Treatment of Cystic Fibrosis with CFTR Modulators].

Pneumologie (Stuttgart, Germany) - 1 May 2016

Tümmler B

Abstract excerpt

Personalized medicine promises that medical decisions, practices and products are tailored to the individual patient. Cystic fibrosis, an inherited disorder of chloride and bicarbonate transport in exocrine glands, is the first successful example of customized drug development for mutation-specific therapy. There are two classes of CFTR modulators: potentiators that increase the activity of CFTR at the cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chloride Channel Agonists
Share to Aminophenols
Share to Aminopyridines
Share to Benzodioxoles
Share to Cystic Fibrosis Transmembrane Conductance Regulator
Share to Drug Combinations
Share to Evidence-Based Medicine
Share to Quinolones

Source

Open in PubMed

Identifiers

PMID: 26894479
DOI: 10.1055/s-0042-100607

Genes

CFTR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics